Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis
https://doi.org/10.24884/1607-4181-2016-23-1-43-46
Abstract
Primary myelofibrosis (PMF) is а chronic BCRABL–negative myeloproliferative disorder with progressive clinical course. Allogeneic stem cell transplantation is the only treatment option
in patients with PMF with curative potential. Most of PMF patients have active disease phase at the moment of alloHSCT. The Januskinase inhibitor ruxolitinib is effective in decreasing
of tumor mass before alloHSCT. Here we report our experience in administration of ruxolitinib as pre and posttransplant therapy of patients with PMF as well as patients with polycythemia vera and essential thrombocythaemia with transformation into myelofibrosis.
About the Authors
M. V. Barabanshchikova
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
E. V. Morozova
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
Yu. Yu. Vlasova
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
V. V. Baykov
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
L. S. Zubarovskaya
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
B. V. Afanasyev
Pavlov First State Medical University of St. Petersburg
Russian Federation
Russian Federation
References
1. Akpek G., Pasquini M. C., Logan B. et al. Effects of spleen status on early outcomes after hematopoietic cell transplantation// Bone Marrow Transplant. –2013. –№ 48(6). –Р. 825–831.
2. Ballen K. K., Shrestha S., Sobocinski K. A. et al. Outcome of Transplantation for Myelofibrosis// Biol. Blood Marrow Transplant. –2010. –№ 16(3). –Р. 358–367.
3. Bradley E. C., EricksonViitanen S., Vaddi K.et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis// NEJM. –2010. –№ 362(15). –Р. 1117–1127.
4. Choi J.L., Alahmari B. et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graftversusleukemia effect// PLoS One. –2014. – № 9(10). –Р. 1117–1127.
5. Eswar T., Saranya K. Experience with Administration of Ruxolitinib after Allogeneic Stem Cell Transplantation (alloSCT) in Patients with Myelofibrosis// Biol. Blood Marrow. Transpl. – 2015. – № 21. –Р. 315.
6. Gangat N., Caramazza D., Vaidya R. et al. DIPSS Plus?: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count and Transfusion Status // JCO. – 2011. – № 29(4). –Р. 392–397.
7. Heine A., Andrea S., Held E. et al. The JAKinhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo // Blood. – 2013. – № 122(7). –Р. 1192–1203.
8. Kroger N., Holler E., Kobbe G. et al. Allogeneic stem cell transplantation after reducedintensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation// Blood.– 2009. – № 114(26). – Р. 5264–5270.
9. Kvasnicka H. M., Van Der Walt J. European consensus on grading bone marrow fibrosis and assessment of cellularity//Haematologica. –2005. – № 90. –Р. 1128–1132.
10. Przepiorka K. H., Weisdorf D., Martin P. Consensus Conference on Acute GVHD Grading// Bone Marrow. Transplant. –1995. – № 15(6). –Р. 825–828.
11. Robin M. Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis?: a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By GoelamsFIM In Collaboration With The Sfgmtc //ASH. –2013. – Abstract 306.
12. Rondelli D., Goldberg J. D., Isola L. et al. MPDRC 101 prospective study of reducedintensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis // Blood. – 2014. – № 124(7). –Р. 1183–1191.
13. Shanavas M., Popat U. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors// Biol. Blood Marrow. Transpl. –2016. – № 22. –Р. 432–440.
14. Stubig T., Alchalby H., Ditschkowski M. et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or postET/PV myelofibrosis // Leukemia. – 2014. – № 28(8). –Р. 1736–1738.
15. Teo S., Tiedt R., Passweg J. R.et al. A GainofFunction Mutation of JAK2 // NEJM. –2005. –№ 352(17). –Р. 1779–1790.
16. Vannucchi A. M., Kantarjian H. M., Kiladjian J.J. et al. A pooled analysis of overall survival in COMFORTI and COMFORTII, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis // Haematologica. –2015. – № 100(9). –Р. 1139–1145.
17. Verstovsek S., Mesa R. A., Gotlib J. et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3year followup of COMFORTI// Haematologica. – 2015. – № 100(4). –Р. 479–488.
18. Zeiser R., Burchert A., Lengerke C. et al. Ruxolitinib in corticosteroidrefractory graftversushost disease after allogeneic stem cell transplantation: a multicenter survey // Leukemia. – 2015. –№ 29(10). –Р. 2062–2068.
Review
For citations:
Barabanshchikova M.V., Morozova E.V., Vlasova Yu.Yu., Baykov V.V., Zubarovskaya L.S., Afanasyev B.V. Application of inhibitor JAK1 and JAK2 ruxolitinib as pre- and posttransplant therapy in patients with myelofibrosis. The Scientific Notes of the Pavlov University. 2016;23(1):43-46. (In Russ.) https://doi.org/10.24884/1607-4181-2016-23-1-43-46
Views:
1160
Email this article 